📊 SKYE Key Takeaways
Is Skye Bioscience, Inc. (SKYE) a Good Investment?
Skye Bioscience exhibits severe financial distress with no revenue generation, cumulative losses of $12.5M, and negative operating cash flow of $8.6M annually, leaving approximately 11 months of cash runway at current burn rate. The company's deteriorating profitability (-93.2% EPS decline YoY), negative returns (ROE -138.8%, ROA -64.4%), and apparent failure to commercialize its pharmaceutical pipeline present fundamental business viability concerns that cannot be offset by its modest liquidity position.
Skye Bioscience, Inc. Key Strengths (SKYE)
- Strong liquidity with 1.78x current ratio, providing short-term operational flexibility
- Minimal leverage with 0.01x debt-to-equity ratio, reducing bankruptcy risk from debt default
- Modest asset base of $19.4M provides some liquidation value cushion
SKYE Stock Risks: Skye Bioscience, Inc. Investment Risks
- Zero or negligible revenue indicates failed commercialization or pre-revenue stage with no near-term monetization
- Annual operating cash burn of $8.6M against $8.1M cash reserves provides less than 12 months of runway at current burn rate
- Negative returns on capital (-138.8% ROE, -64.4% ROA) demonstrate complete destruction of shareholder value
- Deteriorating EPS (-93.2% YoY) indicates worsening operational performance with no recovery trajectory visible
- Pharmaceutical sector execution risk: clinical failure, regulatory rejection, or competitive displacement of pipeline
Key Metrics to Watch
- Operating cash burn rate and remaining cash runway (critical near-term survival metric)
- Revenue generation (any emergence of commercial revenue would dramatically alter thesis)
- Operating loss trend and path to cash flow breakeven
- Clinical trial results and regulatory milestones for pharmaceutical pipeline
Skye Bioscience, Inc. (SKYE) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Skye Bioscience, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
SKYE Profit Margin, ROE & Profitability Analysis
SKYE vs Healthcare Sector: How Skye Bioscience, Inc. Compares
How Skye Bioscience, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Skye Bioscience, Inc. Stock Overvalued? SKYE Valuation Analysis 2026
Based on fundamental analysis, Skye Bioscience, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Skye Bioscience, Inc. Balance Sheet: SKYE Debt, Cash & Liquidity
SKYE Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Skye Bioscience, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.73 indicates the company is currently unprofitable.
SKYE Revenue Growth, EPS Growth & YoY Performance
Skye Bioscience, Inc. Dividends, Buybacks & Capital Allocation
SKYE SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Skye Bioscience, Inc. (CIK: 0001516551)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SKYE
What is the AI rating for SKYE?
Skye Bioscience, Inc. (SKYE) has an AI grade of D with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SKYE's key strengths?
Claude: Strong liquidity with 1.78x current ratio, providing short-term operational flexibility. Minimal leverage with 0.01x debt-to-equity ratio, reducing bankruptcy risk from debt default.
What are the risks of investing in SKYE?
Claude: Zero or negligible revenue indicates failed commercialization or pre-revenue stage with no near-term monetization. Annual operating cash burn of $8.6M against $8.1M cash reserves provides less than 12 months of runway at current burn rate.
What is SKYE's revenue and growth?
Skye Bioscience, Inc. reported revenue of N/A.
Does SKYE pay dividends?
Skye Bioscience, Inc. does not currently pay dividends.
Where can I find SKYE SEC filings?
Official SEC filings for Skye Bioscience, Inc. (CIK: 0001516551) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SKYE's EPS?
Skye Bioscience, Inc. has a diluted EPS of $-0.32.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is SKYE's fundamental grade?
Based on our AI fundamental analysis in June 2026, Skye Bioscience, Inc. has a D grade with 92% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is SKYE stock overvalued or undervalued?
Valuation metrics for SKYE: ROE of -138.8% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is SKYE's AI grade for 2026?
Our dual AI analysis gives Skye Bioscience, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SKYE's free cash flow?
Skye Bioscience, Inc.'s operating cash flow is $-8.6M, with capital expenditures of $0.0.
How does SKYE compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -138.8% (avg: 15%), current ratio 1.78 (avg: 2).